Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Key Points

• Monopar Therapeutics reported quarterly EPS of ($0.79), missing analysts’ consensus estimate of ($0.66) by $0.13.
• Shares fell 0.1% to $114.30 during midday trading, while the stock remains near its 52-week high of $124.82.
• Analysts maintain a generally positive outlook, with an average rating of “Buy” and a consensus price target of $112.08; institutional investors own 1.83% of the company.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.13), FiscalAI reports.

Monopar Therapeutics Stock Down 0.1%

Shares of MNPR traded down $0.16 during mid-day trading on Wednesday, reaching $114.30. The company's stock had a trading volume of 184,271 shares, compared to its average volume of 221,278. The company has a market cap of $765.70 million, a price-to-earnings ratio of -60.16 and a beta of 1.47. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $124.82. The business has a fifty day moving average of $92.93 and a 200 day moving average of $70.68.

Wall Street Analyst Weigh In

A number of analysts recently commented on MNPR shares. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, BTIG Research lifted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $112.08.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter worth approximately $219,000. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 79.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company's stock valued at $15,274,000 after buying an additional 103,909 shares during the period. Virtus Investment Advisers LLC purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $233,000. Millennium Management LLC lifted its position in Monopar Therapeutics by 945.5% in the 4th quarter. Millennium Management LLC now owns 76,674 shares of the company's stock worth $5,007,000 after buying an additional 69,340 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company's stock valued at $85,908,000 after buying an additional 30,042 shares during the period. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source